» Articles » PMID: 3500259

Comparison of the Effector Functions of Human Immunoglobulins Using a Matched Set of Chimeric Antibodies

Overview
Journal J Exp Med
Date 1987 Nov 1
PMID 3500259
Citations 189
Authors
Affiliations
Soon will be listed here.
Abstract

Cell lines have been established that secrete a matched set of human chimeric IgM, IgG1, IgG2, IgG3, IgG4, IgE, and IgA2 antibodies that are directed against the hapten 4-hydroxy-3-nitrophenacetyl. These chimeric antibodies secreted from mouse plasmacytoma cells behave exactly like their authentic human counterparts in SDS-PAGE analysis, binding to protein A and in a wide range of serological assays. The antibodies have been compared in their ability to bind human C1q as well as in their efficacy in mediating lysis of human erythrocytes in the presence of human complement. A major conclusion to emerge is that whereas IgG3 bound C1q better than did IgG1, the chimeric IgG1 was much more effective than all the other IgG subclasses in complement-dependent hemolysis. The IgG1 antibody was also the most effective in mediating antibody-dependent cell-mediated cytotoxicity using both human effector and human target cells. These results suggest that IgG1 might be the favoured IgG subclass for therapeutic applications.

Citing Articles

Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant.

Aurelia L, Purcell R, Theisen R, Kelly A, Esterbauer R, Ramanathan P Sci Adv. 2025; 11(9):eads1482.

PMID: 40009690 PMC: 11864192. DOI: 10.1126/sciadv.ads1482.


Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors.

Hale G, De Vos J, Davy A, Sandra K, Wilkinson I MAbs. 2024; 16(1):2402701.

PMID: 39279104 PMC: 11407402. DOI: 10.1080/19420862.2024.2402701.


Living in LALA land? Forty years of attenuating Fc effector functions.

Hale G Immunol Rev. 2024; 328(1):422-437.

PMID: 39158044 PMC: 11659930. DOI: 10.1111/imr.13379.


Single cell transcriptomes and multiscale networks from persons with and without Alzheimer's disease.

Wang Q, Antone J, Alsop E, Reiman R, Funk C, Bendl J Nat Commun. 2024; 15(1):5815.

PMID: 38987616 PMC: 11237088. DOI: 10.1038/s41467-024-49790-0.


Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4.

Zeng J, Fang Y, Zhang Z, Lv Z, Wang X, Huang Q Oncogene. 2024; 43(29):2244-2252.

PMID: 38806619 PMC: 11245388. DOI: 10.1038/s41388-024-03066-5.


References
1.
Spiegelberg H . Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol. 1974; 19(0):259-94. DOI: 10.1016/s0065-2776(08)60254-0. View

2.
Liu A, Robinson R, Hellstrom K, Murray Jr E, Chang C, Hellstrom I . Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A. 1987; 84(10):3439-43. PMC: 304886. DOI: 10.1073/pnas.84.10.3439. View

3.
Winkelhake J . Immunoglobulin structure and effector functions. Immunochemistry. 1978; 15(9):695-714. DOI: 10.1016/0161-5890(78)90044-5. View

4.
Reth M, Rajewsky K . Analysis of the repertoire of anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) antibodies in C 57 BL/6 mice by cell fusion. II. Characterization of idiotopes by monoclonal anti-idiotope antibodies. Eur J Immunol. 1979; 9(12):1004-13. DOI: 10.1002/eji.1830091216. View

5.
Galfre G, Milstein C . Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981; 73(Pt B):3-46. DOI: 10.1016/0076-6879(81)73054-4. View